A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer

Trial Profile

A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs TPIV 100 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors TapImmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Sep 2016 According to TapImmune media release, the company has requested a pre-Investigational New Drug (IND) meeting with the FDA and submitted questions to the FDA related to opening the IND, and a response from the FDA is expected in September and it anticipates having an open IND by year-end pending comments from FDA.
    • 07 Dec 2015 According to a TapImmune Inc. media release, data will be presented at the 2015 San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top